Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2010 Aug;71(4):252–258. doi: 10.1016/j.curtheres.2010.08.002

Effects of ezetimibe on glucose metabolism in patients with type 2 diabetes: A 12-week, open-label, uncontrolled, pilot study

Tsuyoshi Nozue 1,*, Ichiro Michishita 1, Ichiro Mizuguchi 1
PMCID: PMC3969592  PMID: 24688147

Abstract

Background: A potential effect of ezetimibe, a novel cholesterol-absorption inhibitor, on insulin resistance has been reported in an animal model.

Objective: The aim of this study was to evaluate the effects of ezetimibe on glucose metabolism in patients with type 2 diabetes mellitus (T2DM).

Methods: Between March and June 2008, outpatients with T2DM who were being treated at Yokohama Sakae Kyosai Hospital, Yokohama, Japan, were enrolled in this pilot study if they had not achieved the target lipid levels recommended by the Japan Atherosclerosis Society Guidelines despite diet and exercise or a statin therapy for ≥3 months. At baseline and at 4 and 12 weeks after open-label treatment with ezetimibe 10 mg/d, the levels of lipid parameters, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and high-sensitivity C-reactive protein were measured. Adverse effects (AEs) were assessed at each study visit by patient interviews and laboratory testing.

Results: A total of 21 consecutive patients (10 men, 11 women; mean [SD] age, 72 [9] years; weight, 63.4 [10.5] kg; body mass index, 25.5 [3.2] kg/m2) were enrolled in this study. The mean (SD) level of LDL-C decreased significantly from 146 (31) to 114 (27) mg/dL (−21%; P < 0.001) after 12 weeks of treatment with ezetimibe. The mean level of remnant-like particle cholesterol also decreased significantly from 6.5 (3.8) to 4.8 (2.2) mg/dL (−15%; P = 0.03). Treatment with ezetimibe was associated with a reduction in FPG level from 127 (31) to 119 (30) mg/dL (P = 0.02), and HbAlc from 6.3% (0.6%) to 6.1% (0.7%) (P = 0.003). No AEs were observed or reported during the study period.

Conclusion: In this small, open-label, uncontrolled, pilot study, ezetimibe was associated with a significant decrease in lipid parameters and improvement in glucose metabolism in these patients with T2DM.

Key words: cholesterol, type 2 diabetes mellitus, ezetimibe, RLP-C

Full Text

The Full Text of this article is available as a PDF (415.7 KB).

References

  • 1.van Heek M, Farley C, Compton DS. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129:1748–1754. doi: 10.1038/sj.bjp.0703235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.van Heek M, Farley C, Compton DS. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134:409–417. doi: 10.1038/sj.bjp.0704260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Altmann SW, Davis HR, Jr, Zhu LJ. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204. doi: 10.1126/science.1093131. [DOI] [PubMed] [Google Scholar]
  • 4.Dujovne CA, Ettinger MP, McNeer JF, Ezetimibe Study Group Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–1097. doi: 10.1016/s0002-9149(02)02798-4. [published correction appears in Am J Cardiol. 2003;91:1399] [DOI] [PubMed] [Google Scholar]
  • 5.Knopp RH, Dujovne CA, Le Beaut A, Ezetimibe Study Group Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003;57:363–368. [PubMed] [Google Scholar]
  • 6.Deushi M, Nomura M, Kawakami A. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007;581:5664–5670. doi: 10.1016/j.febslet.2007.11.023. [DOI] [PubMed] [Google Scholar]
  • 7.Masuda D, Nakagawa-Toyama Y, Nakatani K. Ezetimibe improves postprandial hyperlipidaemia in patients with type lib hyperlipidaemia. Eur J Clin Invest. 2009;39:689–698. doi: 10.1111/j.1365-2362.2009.02163.x. [DOI] [PubMed] [Google Scholar]
  • 8.Shimano H, Arai H, Harada-Shiba M. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb. 2008;15:116–121. doi: 10.5551/jat.e560. [DOI] [PubMed] [Google Scholar]
  • 9.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197. doi: 10.2337/diacare.20.7.1183. [DOI] [PubMed] [Google Scholar]
  • 10.Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb. 2010;17:37–44. doi: 10.5551/jat.1651. [DOI] [PubMed] [Google Scholar]
  • 11.Boden G, Laakso M. Lipids and glucose in type 2 diabetes: What is the cause and effect? Diabetes Care. 2004;27:2253–2259. doi: 10.2337/diacare.27.9.2253. [DOI] [PubMed] [Google Scholar]
  • 12.Bajaj M, Suraamornkul S, Kashyap S. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:4649–4655. doi: 10.1210/jc.2004-0224. [DOI] [PubMed] [Google Scholar]
  • 13.Davis HR, Jr, Zhu LJ, Hoos LM. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279:33586–33592. doi: 10.1074/jbc.M405817200. [DOI] [PubMed] [Google Scholar]
  • 14.Temel RE, Tang W, Ma Y. Hepatic Niemann-Pick Cl-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968–1978. doi: 10.1172/JCI30060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–152. doi: 10.1172/JCI22422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rossebø AB, Pedersen TR, Boman K, SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356. doi: 10.1056/NEJMoa0804602. [DOI] [PubMed] [Google Scholar]
  • 17.Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1. [published corrections appear in Lancet. 2008;371:2084 and Lancet. 2005;366:1358] [DOI] [PubMed] [Google Scholar]
  • 18.Peto R, Emberson J, Landray M. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357–1366. doi: 10.1056/NEJMsa0806603. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES